Global InformationElapegademase information
| Clinical data | |
|---|---|
| Trade names | Revcovi |
| Other names | elapegademase-lvlr |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Intramuscular |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
|
| DrugBank |
|
| UNII |
|
| KEGG |
|
Elapegademase, sold under the brand name Revcovi, is a medication for the treatment of the rare disease adenosine deaminase deficiency-SCID in children and adults.[1]
It is a recombinant enzyme[2] that is administered weekly by intramuscular injection.[3]
Elapegademase may interact with PEGylated drugs.[3]
Elapegademase-lvlr was approved by the U.S. Food and Drug Administration (FDA) in 2018.[4][5][6] Leadiant Biosciences was awarded a priority review voucher for its development under the pediatric rare diseases program.[7]
- ^ Skidmore-Roth L (2022). "Elapegademase". Mosby's 2023 Nursing Drug Reference. Elsevier Health Sciences. p. 429. ISBN 978-0-323-93330-8.
- ^ "Elapegademase: Drug Information". www.uptodate.com. Retrieved 28 March 2019.
- ^ a b "LexiComp: Elapegademase-lvlr". LexiComp. Retrieved 28 March 2019.
- ^ "Drug Approval Package: Revcovi". U.S. Food and Drug Administration (FDA). 7 November 2018. Retrieved 26 December 2019.
- ^ "Elapegademase-lvlr Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 26 December 2019.
- ^ "Drug Trial Snapshot: Revcovi". U.S. Food and Drug Administration (FDA). 5 October 2018. Retrieved 26 December 2019.
- ^ "Elapegademase - Leadiant Biosciences". AdisInsight. Springer Nature Switzerland AG. Retrieved 28 March 2019.